Loading...
•
Mar 31, 2024
Phibro Q3 2024 Earnings Report
Phibro Animal Health Corporation reported an increase in net sales and adjusted EBITDA, but a decrease in net income and diluted earnings per share.
Key Takeaways
Phibro Animal Health Corporation announced its third quarter results, showing a 7% increase in net sales to $263.2 million and a 9% increase in Adjusted EBITDA to $29.7 million. However, net income decreased by $1.6 million to $8.4 million, and diluted earnings per share decreased by $0.04 to $0.21. The company has updated its financial guidance for the year ending June 30, 2024, projecting net income between $7 million and $12 million, and diluted EPS between $0.17 and $0.30.
Net sales increased by 7% to $263.2 million.
Net income decreased by $1.6 million to $8.4 million.
Adjusted EBITDA increased by 9% to $29.7 million.
Adjusted diluted EPS increased by 9% to $0.31.
Phibro
Phibro
Phibro Revenue by Segment
Revenue by Segment
Animal Health Revenue
CapyFin.comMFAs and Other Revenue
CapyFin.comNutritional Specialties Revenue
CapyFin.comVaccines Revenue
CapyFin.comMineral Nutrition Revenue
CapyFin.comPerformance Products Revenue
CapyFin.com Forward Guidance
Phibro has updated its fiscal year 2024 guidance, reflecting recent developments including acquisition-related expenses and insurance proceeds. The guidance is on a standalone basis without giving effect to the acquisition of Zoetis’ Medicated Feed Additive portfolio.
Revenue & Expenses
Visualization of income flow from segment revenue to net income